Skip to content

Advertisement

  • Meeting abstract
  • Open Access

Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions

  • 1, 2,
  • 1, 2, 3,
  • 4,
  • 5,
  • 4,
  • 3,
  • 1, 2,
  • 1, 2,
  • 1, 2, 3,
  • 5,
  • 6,
  • 4,
  • 4,
  • 1, 2, 3,
  • 7,
  • 8,
  • 9, 10,
  • 11,
  • 2, 3, 12,
  • 4 and
  • 1, 2, 3
Clinical EpigeneticsThe official journal of the Clinical Epigenetics Society20135 (Suppl 1) :S5

https://doi.org/10.1186/1868-7083-5-S1-S5

  • Published:

Keywords

  • Gene Cluster
  • Transcriptional Regulation
  • Large Region
  • Complete Loss
  • Chromatin Structure

Large regions of recurrent genomic loss are common in cancers; however, with a few well-characterized exceptions, how they contribute to tumor pathogenesis remains largely obscure. Here we identified primate-restricted imprinting of a gene cluster on chromosome 20 in the region commonly deleted in chronic myeloid malignancies. We showed that a single heterozygous 20q deletion consistently resulted in the complete loss of expression of the imprinted genes L3MBTL1 and SGK2, indicative of a pathogenetic role for loss of the active paternally inherited locus. Concomitant loss of both L3MBTL1 and SGK2 dysregulated erythropoiesis and megakaryopoiesis, 2 lineages commonly affected in chronic myeloid malignancies, with distinct consequences in each lineage. We demonstrated that L3MBTL1 and SGK2 collaborated in the transcriptional regulation of MYC by influencing different aspects of chromatin structure. L3MBTL1 is known to regulate nucleosomal compaction, and we here showed that SGK2 inactivated BRG1, a key ATP-dependent helicase within the SWI/SNF complex that regulates nucleosomal positioning. These results demonstrate a link between an imprinted gene cluster and malignancy, reveal a new pathogenetic mechanism associated with acquired regions of genomic loss, and underline the complex molecular and cellular consequences of "simple" cancer-associated chromosome deletions.

Authors’ Affiliations

(1)
Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, UK
(2)
Department of Hematology, University of Cambridge, Cambridge, UK
(3)
Department of Hematology, Addenbrooke’s Hospital, Cambridge, UK
(4)
Department of Physiology, Development, and Neuroscience, University of Cambridge, Cambridge, UK
(5)
A*STAR Singapore Institute for Clinical Sciences, Brenner Centre for Molecular Medicine, Singapore
(6)
Department of Zoology, University of Melbourne, Melbourne, Victoria, Australia
(7)
Department of Hematological Medicine, King’s College London, London, UK
(8)
Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
(9)
Hopital Saint-Louis, AP-HP, Centre d’Investigations Cliniques, Paris, France
(10)
Université Paris 7 Denis Diderot, Paris, France
(11)
Center for Cancer Research and Cell Biology, Queen’s University, Belfast, UK
(12)
Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK

Copyright

© Aziz et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement